How Will The Ribonucleic Acid (RNA) Therapy Clinical Trials Market Reach $3.25 Billion By 2029 Amid Global Shifts?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Current Size And Growth Outlook For The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
The market size for clinical trials in ribonucleic acid (RNA) therapy has been notably expanding in the past few years. The market’s growth is forecast to escalate from $2.57 billion in 2024 to a substantial $2.70 billion in 2025 with a compound annual growth rate (CAGR) maintained at 5.0%. This surge during the historical period is a result of heightened demand for innovative therapies, improved outcome of mRNA vaccines, increased funding for research, amplified activity in clinical trials, and an escalated demand for comparative genomics.
In the coming years, the market size for clinical trials of ribonucleic acid (RNA) therapy is anticipated to consistently expand. It is projected to reach $3.25 billion in 2029, growing at a compound annual growth rate (CAGR) of 4.8%. Reasons for growth during the forecast period include escalating occurrences of uncommon diseases, a surge in regulatory approvals, expanding investment in clinical studies, a growing number of patients participation, and an elevated focus on individualized medicine. Noteworthy trends during this period are improvements in RNA delivery systems, progression in trial designs driven by biomarkers, the incorporation of artificial intelligence in trial formulation, the use of technology in decentralized clinical trials, and innovation in regulatory fast-track channels.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25896&type=smp
What Growth-Enabling Forces Are Impacting The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
The growth of the ribonucleic acid (RNA) therapy clinical trials market is anticipated to be propelled by the rising prevalence of infectious diseases. Such diseases, characterized by the invasion, multiplication, and consequent impairment of health by harmful microorganisms like bacteria, fungi, parasites, or viruses, have seen a surge primarily due to increasing global travel. This enhances the swift transmission of pathogens across different regions and populations. Ribonucleic acid (RNA) therapy clinical trials can aid in battling infectious diseases by fostering the creation and assessment of specialized treatments capable of swiftly adjusting to new pathogens. For example, an April 2025 report from the Minnesota Department of Health, a state agency in the United States, noted that the ratio of HIV cases among males aged 35 to 39 rose from 10% in 2023 to 17% in 2024. As such, the escalating prevalence of infectious diseases is fueling the expansion of the ribonucleic acid (RNA) therapy clinical trials market.
How Does The Ribonucleic Acid (RNA) Therapy Clinical Trials Market Differ By Segment?
The ribonucleic acid (rna) therapy clinical trials market covered in this report is segmented –
1) By Modality: Ribonucleic Acid (RNA) Interference, Antisense Therapy, Messenger Ribonucleic Acid (RNA), Oligonucleotide, Non-Antisense, Non-Ribonucleic Acid Interference (RNAi)
2) By Clinical Trials Phase: Phase I, Phase II, Phase III, Phase IV
3) By Therapeutic Areas: Rare Diseases, Anti-Infective, Anticancer, Neurological, Alimentary Or Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas
Subsegments:
1) By Ribonucleic Acid (RNA) Interference: Small Interfering RNA (siRNA) Therapy Trials, MicroRNA (miRNA)-Based Therapy Trials, Short Hairpin RNA (shRNA) Therapy Trials, Dicer Substrate RNA Therapy Trials
2) By Antisense Therapy: Gapmer Antisense Oligonucleotide Trials, Steric Blocking Antisense Trials, Splice-Switching Antisense Oligonucleotide Trials, Antisense Oligonucleotide-Conjugated Delivery Trials
3) By Messenger Ribonucleic Acid (RNA): mRNA-Based Vaccines Trials, Self-Amplifying mRNA (saRNA) Therapy Trials, Non-Replicating mRNA Therapy Trials, Circular mRNA Therapy Trials
4) By Oligonucleotide: Phosphorothioate Oligonucleotide Trials, Peptide Nucleic Acid (PNA) Trials, Locked Nucleic Acid (LNA) Trials, Morpholino Oligonucleotide Trials
5) By Non-Antisense: RNA Aptamer Therapy Trials, Guide RNA (gRNA)-Mediated CRISPR Trials, RNA Editing Therapy Trials, RNA Scaffolding Or Regulatory RNA Therapy Trials
6) By Non-Ribonucleic Acid Interference (RNAi): Ribozymes Therapy Trials, RNA Decoys Or Sponge RNA Trials, Long Non-Coding RNA (lncRNA) Therapy Trials, Small Activating RNA (saRNA) Therapy Trials
What New Opportunities Are Emerging From Trends In The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
Leading enterprises in the clinical trials market for ribonucleic acid (RNA) therapy are concentrating on producing cutting-edge solutions like RNA-based antisense oligonucleotide therapy clinical trials. These solutions aim to manipulate gene expression and deliver remarkably precise treatments for rare and genetic diseases by targeting specific genetic sequences. RNA-based antisense oligonucleotide therapy clinical trials are studies that explore the use of short synthetic RNA strands to bind to some messenger RNA targets with the goal of modifying gene expression and curing genetic diseases. In December 2024, Sepul Bio, a biotech firm based in France, started the LUNA Phase 2b clinical trial. This trial sought to assess ultevursen, an RNA-based antisense oligonucleotide therapy that targets mutations in exon 13 of the USH2A gene. Such mutations result in retinitis pigmentosa (RP) and Usher syndrome type 2a. The trial, a randomized, double-masked, sham-controlled experiment expected to last two years, will register 81 adults and children aged eight and above from various global locations. The intended patients for the therapy are those suffering from RP or non-syndromic RP due to USH2A’s exon 13 mutations, which are verifiable through genetic testing. The LUNA trial is a continuation of the hopeful results from previous Phase 1/2 examinations, which showed that ultevursen enhanced visual acuity, retinal structure, and retinal sensitivity.
Who Are The Most Influential Companies In The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Charles River Laboratories International Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.
Access The Complete Report Here:
Which Region Is Leading Innovation In The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) therapy clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25896&type=smp
Browse Through More Reports Similar to the Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market 2025, By The Business Research Company
Mrna Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report
Rna Targeting Small Molecules Therapeutics Global Market Report 2025
Cell And Gene Therapy Clinical Trial Services Global Market Report 2025
About The Business Research Company:
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
